// App-Quantinova.ai

OT3-02-05 : NCI-2016-00367: A phase IIB study of neoadjuvant ZT regimen (enzalutamide therapy in combination with weekly paclitaxel) for androgen receptor (AR)-positive triple-negative breast cancer (TNBC)

Researchers

Presenter

  • T Fujii

Principal Investigators

  • B Lim

  • T Helgason

  • KR Hess

  • MZ Gilcrease

  • JS Willey

  • D Tripathy

  • JK Litton

  • S Moulder

  • S Krishnamurthy

  • W Yang

  • JM Reuben

  • WF Symmans

  • NT Ueno

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Leptomeningeal Metastasis

  • Brain metastasis

  • Breast cancer

  • Epilepsy

  • Ulcerative colitis

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

  • Protein Tyrosine Phosphatase, Receptor Type F

Drug/Treatment

  • Enzalutamide

  • Paclitaxel

  • Androgen Tear

  • taxane

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved